Performance of Diffusion and Perfusion MRI in Evaluating Primary Central Nervous System Lymphomas of Different Locations

Overview

Journal BMC Med Imaging

Publisher Biomed Central

Specialty Radiology

Date 2020 Jun 11

PMID 32517711

Citations 1

Authors

Zhen Xing

Nannan Kang

Yu Lin

Xiaofang Zhou

Zebin Xiao

Dairong Cao

Affiliations

Soon will be listed here.

Abstract

Background: Diffusion and perfusion MRI can invasively define physical properties and angiogenic features of tumors, and guide the individual treatment. The purpose of this study was to investigate whether the diffusion and perfusion MRI parameters of primary central nervous system lymphomas (PCNSLs) are related to the tumor locations.

Methods: We retrospectively reviewed the diffusion, perfusion, and conventional MRI of 68 patients with PCNSLs at different locations (group 1: cortical gray matter, group 2: white matter, group 3: deep gray matter). Relative maximum cerebral blood volume (rCBV) from perfusion MRI, minimum apparent diffusion coefficients (ADC) from DWI of each group were calculated and compared by one-way ANOVA test. In addition, we compared the mean apparent diffusion coefficients (ADC) in three different regions of control group.

Results: The rCBV of PCNSLs yielded the lowest value in the white matter group, and the highest value in the cortical gray matter group (P < 0.001). However, the ADC of each subgroup was not statistically different. The ADC of each subgroup in control group was not statistically different.

Conclusion: Our study confirms that rCBV of PCNSLs are related to the tumor location, and provide simple but effective information for guiding the clinical practice of PCNSLs.

Citing Articles

Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.

Wang F, Zhou X, Chen R, Kang J, Yang X, Lin J Eur Radiol. 2023; 33(12):8800-8808.

PMID: 37439934 DOI: 10.1007/s00330-023-09917-1.

References

Kadoch C, Treseler P, Rubenstein J . Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006; 21(5):E1. DOI: 10.3171/foc.2006.21.5.2. View

Zhang Y, Zhang Q, Wang X, Deng X, Zhu Y . Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment. Clin Radiol. 2016; 71(10):1018-1029. DOI: 10.1016/j.crad.2016.05.017. View

Goel S, Duda D, Xu L, Munn L, Boucher Y, Fukumura D . Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91(3):1071-121. PMC: 3258432. DOI: 10.1152/physrev.00038.2010. View

Kuppusamy K, Lin W, Cizek G, Haacke E . In vivo regional cerebral blood volume: quantitative assessment with 3D T1-weighted pre- and postcontrast MR imaging. Radiology. 1996; 201(1):106-12. DOI: 10.1148/radiology.201.1.8816529. View

Lu S, Kim S, Kim N, Kim H, Gon Choi C, Lim Y . Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions. AJR Am J Roentgenol. 2015; 204(4):827-34. DOI: 10.2214/AJR.14.12677. View

McAllister L, Doolittle N, Guastadisegni P, Kraemer D, Lacy C, Crossen J . Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000; 46(1):51-60; discussion 60-1. View

Cha S . Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am. 2004; 11(3):403-13. DOI: 10.1016/s1064-9689(03)00066-7. View

Ginat D, Mangla R, Yeaney G, Schaefer P, Wang H . Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas. Acad Radiol. 2012; 19(8):986-90. DOI: 10.1016/j.acra.2012.04.006. View

Barajas Jr R, Phillips J, Vandenberg S, McDermott M, Berger M, Dillon W . Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015; 70(10):1087-95. DOI: 10.1016/j.crad.2015.03.006. View

10.

Ho C, Cardinal J, Kamer A, Kralik S . Relative cerebral blood volume from dynamic susceptibility contrast perfusion in the grading of pediatric primary brain tumors. Neuroradiology. 2014; 57(3):299-306. DOI: 10.1007/s00234-014-1478-0. View

11.

Koeller K, Smirniotopoulos J, Jones R . Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics. 1997; 17(6):1497-526. DOI: 10.1148/radiographics.17.6.9397461. View

12.

Huang W, Wen J, Wu G, Yin B, Li J, Geng D . Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response. AJNR Am J Neuroradiol. 2016; 37(11):2010-2018. PMC: 7963768. DOI: 10.3174/ajnr.A4867. View

13.

Rubenstein J, Shen A, Batchelor T, Kadoch C, Treseler P, Shuman M . Differential gene expression in central nervous system lymphoma. Blood. 2009; 113(1):266-7. PMC: 2614638. DOI: 10.1182/blood-2008-04-152835. View

14.

Yan R, Haopeng P, Xiaoyuan F, Jinsong W, Jiawen Z, Chengjun Y . Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index. Neuroradiology. 2015; 58(2):121-32. DOI: 10.1007/s00234-015-1606-5. View

15.

Jahnke K, Doolittle N, Muldoon L, Neuwelt E . Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus. 2006; 21(5):E11. DOI: 10.3171/foc.2006.21.5.12. View

16.

Xing Z, You R, Li J, Liu Y, Cao D . Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol. 2013; 24(4):329-36. DOI: 10.1007/s00062-013-0255-5. View

17.

Kansara R, Shenkier T, Connors J, Sehn L, Savage K, Gerrie A . Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015; 90(12):1149-54. DOI: 10.1002/ajh.24204. View

18.

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J . High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014; 83(3):235-9. PMC: 4117362. DOI: 10.1212/WNL.0000000000000593. View

19.

Bjornerud A, Sorensen A, Mouridsen K, Emblem K . T1- and T2*-dominant extravasation correction in DSC-MRI: part I--theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab. 2011; 31(10):2041-53. PMC: 3208149. DOI: 10.1038/jcbfm.2011.52. View

20.

Valles F, Perez-Valles C, Regalado S, Barajas R, Rubenstein J, Cha S . Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2012; 34(1):35-40. PMC: 4134048. DOI: 10.3174/ajnr.A3165. View